Skip to main content

Table 1 The predicted binding energy (kCal/mol) and epitope between antibody (FD006 or bevacizumab) and antigen (VEGFA)

From: Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

  Binding energy (kcal/mol) Identified epitope
FD006-VEGF -168.24 F17M18D19, Y21Q22R23, Y25, L66E67, N100K101
bevacizumab-VEGF -156.35 F17M18D19, Y21Q22R23, Y25, K101
\